Overall, these results strongly suggest that the stable ectopic expression of CXCR4 and IL-10 characteristic of CXCR4-IL10-MSCs should improve the therapeutic efficacy previously characterized in WT-MSCs in alloHSC-transplanted patients developing GvHD. The gene discussed is CXCR4; the disease is graft versus host disease.